ExeVir Bio is an antibody drug developer that develops single-domain antibody-based therapies to help patients defend against viral infections and an antiviral response platform using protein therapeutics constructed from camelid single-domain antibody fragments to stop the spread of the virus. ExeVir Bio, which is developing nanobody-based therapeutics for infectious diseases, recently announced that it has raised €25 million in venture debt from the European Investment Bank (EIB).
This article is transferred from: https://www.itjuzi.com/investevent/13770425
This site is only for collection, and the copyright belongs to the original author.